Procter & Gamble Health informs about disclosure

27 Sep 2023 Evaluate

Pursuant to the provisions of Regulation 30 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Procter & Gamble Health has informed that the Company plans to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective September 30, 2023. The injections portfolio, procured from the Company’s manufacturing facility at Goa, accounted for revenue of Rs 102.92 crores during the financial year 2022-23, constituting 8.37% of the Company’s total revenue. Discontinuation of production at Company’s plant in Goa, shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer. The Company is outsourcing manufacturing of the injection’s portfolio, with an intent to achieve cost efficiency and supply optimization.

The above information is a part of company’s filings submitted to BSE.

Procter&Gamble Healt Share Price

5450.35 -54.55 (-0.99%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.